- Home
- MIST
as 12-17-2024 3:41pm EST
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
| Founded: | 2003 | Country: | Canada |
| Employees: | N/A | City: | MONTREAL |
| Market Cap: | 100.3M | IPO Year: | N/A |
| Target Price: | $13.00 | AVG Volume (30 days): | 372.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.12 - $2.93 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | -80.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Milestone Pharmaceuticals Inc. News
MIST Breaking Stock News: Dive into MIST Ticker-Specific Updates for Smart Investing
GlobeNewswire
23 days ago
Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference
Zacks
a month ago
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright
Associated Press Finance
a month ago
Milestone Pharmaceuticals: Q3 Earnings Snapshot
GlobeNewswire
a month ago
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
Simply Wall St.
2 months ago
Individual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46%
GlobeNewswire
3 months ago
Milestone Pharmaceuticals to Host Investor KOL Event
MT Newswires
3 months ago
Milestone Pharmaceuticals' Partner Ji Xing's Phase 3 Trial of Etripamil Meets Primary Endpoint
GlobeNewswire
3 months ago
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
Compare MIST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MIST Milestone Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.